Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-15

Study Completion Date

2019-09-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase II multicenter, double-blinded clinical trial of the safety and efficacy of

SP160412 in the temporary relief of mild to moderate, (i.e. first degree) sunburn

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model

NCT02666846

Pain

COMPLETED PHASE1

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129

Delayed Onset Muscle Soreness

COMPLETED PHASE2

Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

NCT03639571

Healthy

COMPLETED PHASE1

UVB Model Validation Study

NCT01055249

Pain Inflammation Healthy Volunteers

COMPLETED PHASE1

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634

Delayed Onset Muscle Soreness, DOMS

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of the trial or study, its endpoints, its assumptions and its variables are described below:

Objectives and endpoints Study objectives

The study intends to determine and compare the safety and synergistic efficacy of the combined dosing of Ibuprofen and Chlorpheniramine maleate vs. each of the individual drugs in subjects with mild to moderate ( 1st degree) sunburn.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sunburn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Multi-centers double-blinded clinical trial with one intervention arm with SP160412 (Ibuprofen and Chlorpheniramine combined) with one arm with Active control (Ibuprofen with placebo) and a third arm (Chlorpheniramine with Placebo)

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1 Product SP160412

oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.

Group Type EXPERIMENTAL

SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg

Intervention Type DRUG

2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours

capsules Ibuprofen&placebo

2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,

Group Type PLACEBO_COMPARATOR

2 capsules Ibuprofen and 1 placebo

Intervention Type DRUG

Ibuprofen and placebo

Capsule Chlorpheniramin&placebo

capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route

Group Type PLACEBO_COMPARATOR

capsule Chlorpheniramine 4mg and 1 Placebo

Intervention Type DRUG

Chlorpheniramine 4mg and one capsule Placebo 3/72days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg

2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours

Intervention Type DRUG

2 capsules Ibuprofen and 1 placebo

Ibuprofen and placebo

Intervention Type DRUG

capsule Chlorpheniramine 4mg and 1 Placebo

Chlorpheniramine 4mg and one capsule Placebo 3/72days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

2 Capsules Ibuprofen and one capsules Chlorpheniramine Capsule with Ibuprofen 400 mg with Placebo Active comparator Chlorpheniramine 4 mg with Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* enter the study, a participant must meet all the following criteria:

1. Male or female, with a minimum age of 18 years old.
2. Participant who has experienced sunburn in the past 18 hours before inclusion in the study.
3. Participant who is willing and able to give written informed consent and understand the language used at the investigation site.
4. Participant who is willing and able to administer the investigational medicinal product (IMP) as directed, comply with study instructions and commit to all the follow-up visits for the duration of the study.
5. Participant with a Fitzpatrick skin type I, II or III as clinically defined by the investigator.
6. Participant with a clinical assessment of sunburn score of 2 (mild) or 3 (moderate) according to clinical grading described in Appendix II.2. Clinical Assessment of Sunburn (page 78).
7. Participant who is in good general health and free of any disease state or physical condition except sunburn that might impair the clinical evaluation of erythema, pain and pruritus associated with sunburn.
8. Participant who confirms not having used sunscreen or any other lotion on the zone of investigation before the acquired sunburn and inclusion in the study.
9. Participant who agrees not to expose themself further to the sun and not to apply any topical product (sunscreen, aftersun products, products containing aloe vera, moisturizing products…) on the zone of investigation within 18 hours before sunburn and during the study.
10. If participant is a woman of childbearing potential and declares to be sexually active, she must have a negative urine pregnancy test (UPT) at inclusion and agree to use an effective form of birth control for the duration of the study (e.g., stable dose of oral contraceptives for at least three months before the start of the study, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal). Abstinence is an acceptable form of birth control for participants who are sexually active.

Exclusion Criteria

1. Participant who routinely subjects himself/herself to natural or artificial tanning or the like which, in the investigator's opinion, exposes the participant to an unacceptable risk when taking part in the study.
2. Participant who is pregnant or lactating, or is planning to become pregnant during the study.
3. Participant who is currently enrolled in an investigational product or device study.
4. Participant who has used an investigational product or investigational device treatment within 30 days prior to the start of the study.
5. Participant with a medical condition (including previous history of cardiac disease, renal disease, gastrointestinal bleeding, uncontrolled hypertension) or a medication which, in the clinical investigator's judgement, makes the participant ineligible or places the participant at undue risk during the study.
6. Participant who has a history of drug allergy or sensitivity to NSAIDs, including Aspirin, and/or to Chlorpheniramine maleate, and/or to any of the components of the IMP.
7. Participant who has used pain relieving and/or analgesic medications (e.g. NSAIDs, ASA, opiates, Tramadol, arnica, products containing aloe vera) or psychoactive substances (e.g. marijuana) within 7 days before the start of the study.
8. Participant who has used any topical or oral antihistamine/anti-allergy medications within 7 days prior to the start of the study.
9. Participant who has used any photosensitizing medication (e.g., topical or systemic retinoids, tetracycline or derivatives, etc.) within 30 days of the start of the study. Estrogens as part of birth control agents or hormone replacement therapy are allowed.
10. Participant with acute or chronic pain condition.
11. Participant suffering from asthma.
12. Participant who has a history of any light-sensitive disorder including but not limited to lupus erythematosus, polymorphous light eruption or porphyria.
13. Participant with a personal or family history in a first-degree relative of malignant melanoma, dysplastic nevi or non-melanoma skin cancer.
14. Participant who has received more than one sunburn in the last 6 months in the same zone as the study sunburnt evaluation zone.
15. Participant who has received sunburn or other erythematous skin reaction to light within 21 days prior to the start of the study.
16. Participant with extensive body hair, tattoos or other adornment that would make clinical assessments difficult.
17. Participant who is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No